Novo Nordisk Ups Efforts in Basal Insulin Market, Pits Tresiba against Lantus

Novo's Long-Acting Insulin Analog "Tresiba" Following the launch of its long-acting insulin analog Tresiba (insulin degludec), Novo Nordisk Pharma is intensifying its drive in the Japanese basal insulin market (long-acting/intermediate-acting) to rival Sanofi K.K.’s best-selling Lantus (insulin glargine), which enjoys...read more